You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


Biogen’s inherited eye disease gene therapy misses the mark in late-stage trial

Biogen has announced that a late-stage trial of its gene therapy timrepigene emparvovec did not meet its primary and key secondary endpoints in patients with the rare inherited eye disease choroideremia.